Search results
Results from the WOW.Com Content Network
The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II. The drug or other substance has a currently [1] accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
[8] [2] (Diphenoxlate by itself is a Schedule II controlled substance.) It is on Schedule III of the Single Convention on Narcotic Drugs , only in forms that contain, according to the Yellow List: "not more than 2.5 milligrams of diphenoxylate calculated as base and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of ...
Abuse of the drug or other substances may lead to severe psychological or physical dependence. The complete list of Schedule II substances is as follows. The Administrative Controlled Substances Code Number and Federal Register citation for each substance is included.
Legally speaking, the term "narcotic" may be imprecisely defined and typically has negative connotations. [2] [3] When used in a legal context in the U.S., a narcotic drug is totally prohibited, such as heroin, or one that is used in violation of legal regulation (in this word sense, equal to any controlled substance or illicit drug).
[10] [14] Hydrocodone is a controlled drug: in the United States, it is classified as a Schedule II Controlled Substance. Common side effects include dizziness, sleepiness, nausea, and constipation. [10] Serious side effects may include low blood pressure, seizures, QT prolongation, respiratory depression, and serotonin syndrome. [10]
[2] [3] Benzarone: 1992 Germany Hepatitis. [3] Benziodarone: 1964 France, UK Jaundice. [3] Beta-ethoxy-lacetanilanide: 1986 Germany Renal toxicity, animal carcinogenicity. [3] Bezitramide: 2004 Netherlands Risk of fatal overdose [10] Bithionol: 1967 US Dermatologic toxicity. [3] Brotizolam: 1989 UK Animal carcinogenicity. [3] Bromfenac: 1998 US
This randomized controlled trial included 57 Black and white adult men and women aged 35 to 65 with “mild” type 2 diabetes. They had a hemoglobin A1c (HbA1c) of less than or equal to 8.0% and ...
Their condition is then labeled "ketosis-prone type 2 diabetes". [3] [22] Drugs in the gliflozin class (SGLT2 inhibitors), which are generally used for type 2 diabetes, have been associated with cases of diabetic ketoacidosis where the blood sugars may not be significantly elevated ("euglycemic DKA"). [23]